优化3D卷积神经网络以基于MRI检测阿尔茨海默病
Maitha Alarjani1, Abdulmajeed Almuaibed2
1Computer Science, King Faisal University, Al-Ahsa, Saudi Arabia.
PeerJ. Computer science
|September 24, 2025
概括
这项研究引入了一个3D卷积神经网络 (3D-CNN),用于使用MRI扫描进行早期阿尔茨海默氏病检测. 深度学习模型实现了91%的准确性,为改善诊断和患者结果提供了一个有前途的工具.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 人工智能的人工智能
背景情况:
- 阿尔茨海默氏病 (AD) 是一种渐进的神经系统疾病,导致认知能力下降,症状出现前发生不可逆转的损伤.
- 早期诊断AD对于及时干预,减缓进展和提高患者生活质量至关重要.
- 机器学习和神经成像,特别是用MRI进行深度学习,对早期AD检测有希望.
研究的目的:
- 开发和评估3D卷积神经网络 (3D-CNN) 以提高早期阿尔茨海默病检测的分类准确性.
- 利用OASIS-3数据库和先进的预处理技术来开发强大的诊断模型.
主要方法:
- 开发了一个3D-CNN模型来处理完整的3DMRI扫描,保留空间信息,与2D方法不同.
- 应用了先进的预处理技术,包括强度正常化和降噪,对MRI数据.
- 该模型是使用OASIS-3数据库中的数据进行训练和验证的.
主要成果:
- 拟议的3D-CNN模型在阿尔茨海默病检测方面实现了91%的分类准确性.
- 通过防止在缩小维度过程中信息丢失,3D方法的性能优于传统的2D方法.
- 通过预处理提高图像质量,有助于提高分类性能.
结论:
- 深度学习,特别是开发的3D-CNN,显示出可靠和高效的阿尔茨海默病早期诊断的巨大潜力.
- 这些发现支持使用先进的神经成像和人工智能来改善AD的临床决策.
- 这种方法通过早期干预为更好的患者结果铺平了道路.
关键词:
三维卷积神经网络是3D卷积神经网络.阿尔茨海默病的疾病分类.大脑缩检测检测大脑缩检测数据预处理数据的预处理.深度学习是一种深度学习.磁力共振成像 (MRI) 的体积数据医疗图像处理 医学图像处理神经退行性疾病 神经退行性疾病神经科学是一个神经科学.更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.4K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.7K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
